P
Penelope J. Hallett
Researcher at Harvard University
Publications - 55
Citations - 4328
Penelope J. Hallett is an academic researcher from Harvard University. The author has contributed to research in topics: Substantia nigra & Parkinson's disease. The author has an hindex of 32, co-authored 51 publications receiving 3660 citations. Previous affiliations of Penelope J. Hallett include Istituto Italiano di Tecnologia.
Papers
More filters
Journal ArticleDOI
Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats
Gunnar Hargus,Oliver Cooper,Michela Deleidi,Adam S. Levy,Kristen Lee,Elizabeth Marlow,Alyssa Yow,Frank Soldner,Dirk Hockemeyer,Penelope J. Hallett,Teresia Osborn,Rudolf Jaenisch,Ole Isacson +12 more
TL;DR: The transplantation of human PDiPS cell-derived neurons as a long-term in vivo method to analyze potential disease-related changes in a physiological context is established and proof of principle of survival and functional effects is demonstrated.
Journal ArticleDOI
Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years
Ivar Mendez,Angel Viñuela,Arnar Astradsson,Karim Mukhida,Penelope J. Hallett,Harold A. Robertson,Travis S. Tierney,Renn Holness,Alain Dagher,John Q. Trojanowski,Ole Isacson +10 more
TL;DR: Postmortem analysis of five subjects with Parkinson's disease 9–14 years after transplantation of fetal midbrain cell suspensions revealed surviving grafts that included dopamine and serotonin neurons without pathology.
Journal ArticleDOI
Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease.
Penelope J. Hallett,Michela Deleidi,Arnar Astradsson,Gaynor A. Smith,Oliver Cooper,Teresia Osborn,Maria Sundberg,Michele A. Moore,Eduardo Perez-Torres,Anna-Liisa Brownell,James M. Schumacher,Roger D. Spealman,Ole Isacson +12 more
TL;DR: The finding that unilateral engraftment of CM-iPSCs could provide a gradual onset of functional motor improvement contralateral to the side of dopamine neuron transplantation, and increased motor activity, without a need for immunosuppression supports further development of autologous iPSC-derived cell transplantation for treatment of PD.
Journal ArticleDOI
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
TL;DR: In animal models, NMDA receptor antagonists are effective antiparkinsonian agents and can reduce the complications of chronic dopaminergic therapy (wearing off and dyskinesias).
Journal ArticleDOI
Dopamine D1 Activation Potentiates Striatal NMDA Receptors by Tyrosine Phosphorylation-Dependent Subunit Trafficking
TL;DR: Modification of these pathways may be a useful therapeutic target for Parkinson’s disease and other basal ganglia disorders in which abnormal function of striatal NMDA receptors contributes to the symptoms of the diseases.